Survival rates from lung cancer by patients diagnosed in Scotland is among the lowest in Europe and lung cancer is the biggest killer of all cancers. During a recent meeting the Scottish Parliament in Edinburgh by the Cross-Party Group for Cancer it was agreed that there is a strong demand to consider a formal recommendation
Cancer Research UK is set to conduct a clinical trial for a vaccine considered to be first-of-its-kind for non-small cell lung cancer (NSCLC) based on ‘off-the-shelf’ human stem cells with US firm Asterias Biotherapeutics. CRUK says that if the new vaccine proves to work in clinical trials it could be an option for patients who
A green light has been given for lung cancer drug Keytruda by NICE for the treatment for certain patients in England. Merck, Sharp, and Dohme (MSD)’s Keytruda will be available for those with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC), where tumours have specific protein and genetic markers. Keytruda is the first treatment
NICE has turned down NHS funding for Roche’s Alecensa as a first-line treatment for lung cancer. The public regulatory body denied the drug for untreated ALK-positive advanced non-small-cell lung cancer (NSCLC) in adults. Alecensa was approved Europe late last year after Phase III trial data showed median progression-free survival of 25.7 months for people given
Bristol-Myers Squibb’s Opdivo is being recommended by NICE to treat a certain form of lung cancer on the NHS in England, via the Cancer Drugs Fund. The cost watchdog has issued a Final Appraisal Determination (FAD) recommending that the drug’s use to treat both squamous and non-squamous forms of non-small cell lung cancer (NSCLC), after
Roche’s Alecensa has shown strong results in two studies looking at its benefits in ALK positive non-small cell lung cancer (NSCLC) patients, both in first line use and a second line setting. Alecensa is directly competing against the established drug for ALK+ lung cancer, Pfizer’s Xalkori, and has already proved itself to be superior in
Results from a survey analysing the prescribing behaviour of 500 European physicians treating patients with advanced non-small cell lung cancer (NSCLC) have been published in Clinical Lung Cancer. The research examined the primary therapy goal of physicians and their choice of treatment for patients with advanced adenocarcinoma of the lung, after first-line chemotherapy. An overview
